Ad5-105K
Candidate Overview
The Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) developed by CanSino Biologics Inc. is a non-replicating viral-vectored vaccine intended for administration via nebulized inhalation by mouth. It is designed to induce both local mucosal immunity in the respiratory tract and systemic immune responses against Mycobacterium tuberculosis (Mtb).
The adenovirus type 5 (Ad5) backbone functions as a gene delivery vector, enabling transient expression of the Mtb antigens Ag85A, Mtb32A, and Mtb39A in host cells. The vaccine is provided in a liquid formulation and is nebulized immediately prior to administration. Before vaccination, the vaccine is converted into an aerosol mist using a nebulization device, allowing deposition of the vaccine in the respiratory tract.
Sponsor / Lead Developer: CanSino Biologics Inc.
Development partner(s): PT Etana Biotechnologies Indonesia
Clinical Trial Status: Active Trials
Primary Indication: Prevention of TB disease
Other Indication(s): Prevention of Mtb infection or sustained infection and Prevention of TB recurrence
Target Population(s): Adolescents, Adults, Children, People living with HIV, People with Mtb infection, and People without Mtb infection
Target Route of Administration: Aerosol
Clinical Trials
ACTIVE TRIALS |
|
| Registry Listing | NCT06732583 |
| Clinical Trial Phase | Phase 1 |
| Clinical Trial Sponsor | CanSino Biologics, Inc. |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
| People with Mtb infection | |